Abstract
8 toll adolescents (4 boys and 4 girls) had accepted to bo treated by SMS 201-995 for 12 Months in order to reduce their growth velocity and therefore their adult height. This treatment had been submitted to the local ethical committee. Afc present time 5 patients had undergone 3 months treatment (4 boys and one girl), mean chronological age was 14 years 6 months ± 1 year 2 months, mean SD for height was + 3.1 ± 0.42 SD, mean bone age was 14 years 6 Months ± 1 year 3 months, pubertal development was scored Tanner stage III (n=l) and IV (n=4). Before treatment, physiological 24 hour GH secretion, GH response to TRH and GHRH stimulation tests, SmC levels and others pituitary functions were evaluated. SMS 201-995 was given twice daily using 2 subcutaneous injection of 250 ug at 8.00 AM and 8.00 PM. For the whole group, growth velocity had strongly decreased (2 ± 2.82 cm/y versus 6.9 ± 2.35 cm/y), growth was completely blocked in 3 patients. One boy aged 15 years 9 months had the same growth velocity before and after treatment. The last patient had previously been treated unsuccessfully by bromocryptine during one year and after 3 months of SMS 201-995 therapy growth velocity had decreased (6cm/y versus 10 cm/y before treatment). Tolerance of this therapy was good however transient diarrhea and nausea during the first ten days had occured in all cases. Routine biological parameters remained normal. CONCLUSION : These preliminary results suggest the efficacy of SMS 201–995 in reducing growth velocity in children with constitutional tall stature without major side effects.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
